Drug patent live and generic competition: Analysis of new molecular entities approved by the FDA between 1980 and 1999

Journal of Pharmaceutical Finance, Economics and Policy

Volumn 16, Issue 4, 2008, Pages 67-85

  Seoane Vazquez, Enrique C ^a   Schondelmeyer, Stephen W ^b   Szeinbach, Sheryl L ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Drug exclusivity; Drug patents; New molecular entities

Indexed keywords

GENERIC DRUG; MOLECULAR THERAPY AGENT; NEW DRUG; ORPHAN DRUG;

ARTICLE; DRUG APPROVAL; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; PATENT; PEDIATRICS; PRIORITY JOURNAL; UNITED STATES;

EID: 66249084667     PISSN: 15385698     EISSN: 15385396     Source Type: Journal    
DOI: 10.1080/15385690801963530     Document Type: Article

References (16)

1. Bae, J.P. 1997. Drug patent expirations and the speed of generic entry. Health Services Research 32, no.1: 87-101.
2. Caves, R.E., M.D. Whinston, and M.A. Hurwitz. 1991. Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Papers on Economic Activity, Microeconomics, 1-48.
3. DeBari, V.J. 1993. International harmonization of patent law: A proposed solution to the United States' first to file debate. Fordham International Law Journal 16: 687-720.
4. Eisman, M.M., and W.M. Wardell. 1981. The decline in effective patent life of new drugs. Research Management 21, no.1: 18-21.
5. Grabowski, H.G., and J.M. Vernon. 1983. The regulation of pharmaceuticals: Balancing the benefits and risks. Washington: American Enterprise Institute for Public Policy Research.
6. Grabowski, H.G., and J.M. Vernon. 1996. Longer patents for increased generic competition in the US. TheWaxman-Hatch Act after one decade. Pharmacoeconomics 10(Suppl. no. 2): 110-123
7. Grabowski, H.G., and J.M. Vernon. 2000. Effective patent life in pharmaceuticals. International Journal of Technical Management 19, no. 1/2: 98-120.
8. Griliches, Z., and I. Cockburn. 1994. Generics and new goods in pharmaceutical price indexes. American Economic Review 84, no.5: 1213-1233
9. Heinrich, J. 2001. Pediatric drug research: Substantial increase in studies of drugs for children, but some challenges remain. Testimony before the committee on health, education, labor and pensions,U.S. Senate.Washington, DC:United StatesGeneral Accounting Office.
10. Kaitin, K.I., and J.A. DiMasi. 2000. Measuring the pace of new drug development in the user fee era. Drug Information Journal 34, no.3: 673-680
11. Nordhaus,W.D. 1969. Invention growth, and economic welfare: A theoretical treatment of technological change. Cambridge, MA: MIT Press.
12. Schondelmeyer, S.W. 1995. Economic impact of GATT patent extension on currently marketed drugs. Minneapolis, MN: PRIME Institute, University of Minnesota.
13. Scotchmer, S. 1991. Standing on the shoulders of giants: Cumulative research and the patent law. Journal of Economic Perspectives 5, no.1: 29-41.
14. Smith K.B. 1994. (Advertisement), Scrip, 1927:16.
15. United States General Accounting Office. 2002. Food and drug administration. Effect of user fees on drug approval times, withdrawals, and other agency activities. Washington, DC: United States General Accounting Office.
16. U.S. Food and Drug Administration. 2001. The pediatric exclusivity provision. Status report to Congress. Washington, DC: U.S. Food and Drug Administration. http://www.fda.gov/cder/pediatric/reportcong01.pdf.